Comments on: Roche Spins NJ Exit As Recruiters Eye Genentech http://www.pharmalot.com/2008/08/roche-spins-nj-departure-as-recruiters-eye-genentech/ News, Comment and Conversation Fri, 10 Feb 2012 21:10:11 +0000 http://wordpress.org/?v=2.6.2 By: John Wisp http://www.pharmalot.com/2008/08/roche-spins-nj-departure-as-recruiters-eye-genentech/#comment-370770 John Wisp Mon, 01 Sep 2008 03:21:16 +0000 http://www.pharmalot.com/?p=15137#comment-370770 "Laundry" and "Pharma Monkey" know what they're talking about. "mrpas" is basic investor who deals only in dollars and cents like the bean counters at Roche. "mrpas", if basic research should only be left to academia then the pace of all research marches at academia's pace. Too slow for biotechs. DNA took a huge leap of faith in funding its basic research to accelerate their scienctific knowledge needed to bring the next block buster drug to market. It was risky, but it has paid off handsomely for science, investors, and patients. If left alone, Genentech could have done more. The buyout is inevitable. The "basic" researchers will take their passion and know how else where. Roche will be left with large debt, empty buildings, no ingenuity, and no way to save themselves when DNA's patents run out. John p.s. It is very very easy to hide behind a mask as you have "mrpas" and sling mud. “Laundry” and “Pharma Monkey” know what they’re talking about. “mrpas” is basic investor who deals only in dollars and cents like the bean counters at Roche.

“mrpas”, if basic research should only be left to academia then the pace of all research marches at academia’s pace. Too slow for biotechs. DNA took a huge leap of faith in funding its basic research to accelerate their scienctific knowledge needed to bring the next block buster drug to market. It was risky, but it has paid off handsomely for science, investors, and patients.
If left alone, Genentech could have done more. The buyout is inevitable. The “basic” researchers will take their passion and know how else where. Roche will be left with large debt, empty buildings, no ingenuity, and no way to save themselves when DNA’s patents run out.

John

p.s. It is very very easy to hide behind a mask as you have “mrpas” and sling mud.

]]> By: Pharma Monkey http://www.pharmalot.com/2008/08/roche-spins-nj-departure-as-recruiters-eye-genentech/#comment-370067 Pharma Monkey Mon, 25 Aug 2008 01:56:33 +0000 http://www.pharmalot.com/?p=15137#comment-370067 "Mrpas" is voicing the exactly same kind of myopic and self-righteous opinion that is currently costing billions of dollars to almost all major pharma. Basic research is essential to the health of pharma, and it is doubly so these days when academia is starving from very regrettable lack of funding. It has been shown time and time again that once a larger company acquires a smaller one and lets go of these loathsome basic researchers - the internal productivity levels of the combined new entity go down the drain. The crude and trivialistic outlook exemplified by the statements made by "Mrpas" is one of the root causes of the decline of Pharma science (and therefore the new drug discovery) in the West. We can only hope that the strip-mining MBAs see the error of their ways before it's too late. “Mrpas” is voicing the exactly same kind of myopic and self-righteous opinion that is currently costing billions of dollars to almost all major pharma.

Basic research is essential to the health of pharma, and it is doubly so these days when academia is starving from very regrettable lack of funding. It has been shown time and time again that once a larger company acquires a smaller one and lets go of these loathsome basic researchers - the internal productivity levels of the combined new entity go down the drain.

The crude and trivialistic outlook exemplified by the statements made by “Mrpas” is one of the root causes of the decline of Pharma science (and therefore the new drug discovery) in the West. We can only hope that the strip-mining MBAs see the error of their ways before it’s too late.

]]> By: Laundry http://www.pharmalot.com/2008/08/roche-spins-nj-departure-as-recruiters-eye-genentech/#comment-369904 Laundry Sat, 23 Aug 2008 15:58:51 +0000 http://www.pharmalot.com/?p=15137#comment-369904 Mrpas: like parents who think students should only spend time learning "academic stuff" and quit "wasting" time on games, you make a mistake by misunderstanding drug (or child) development. Genentech's basic research really does get it closer to successful drug development. First, it has made it possible to recruit and retain the best and brightest,since they value the publication culture and the recognition it brings. Second, they are just practicing the latest techniques that are needed on the "real" drug development work. Every lesson learned is applied to further success on the drug side. The attitude you voice is understandable on the surface but deeply self-destructive in the longer run, and exactly the kind of worrysome mis-management that could kill the golden goose. Mrpas: like parents who think students should only spend time learning “academic stuff” and quit “wasting” time on games, you make a mistake by misunderstanding drug (or child) development. Genentech’s basic research really does get it closer to successful drug development. First, it has made it possible to recruit and retain the best and brightest,since they value the publication culture and the recognition it brings. Second, they are just practicing the latest techniques that are needed on the “real” drug development work. Every lesson learned is applied to further success on the drug side. The attitude you voice is understandable on the surface but deeply self-destructive in the longer run, and exactly the kind of worrysome mis-management that could kill the golden goose.

]]> By: mrpas http://www.pharmalot.com/2008/08/roche-spins-nj-departure-as-recruiters-eye-genentech/#comment-369814 mrpas Fri, 22 Aug 2008 14:52:19 +0000 http://www.pharmalot.com/?p=15137#comment-369814 Genentech is supposed to be a company responsible for investors returns. It is a doing a great job of bringing products and generating revenues; at the same time, like academic institutions, it is wasting a lot of money in basic research that does produce papers in Science and Nature, but better done at academic institutions rather than a money-making machine. One Roche acquires Genentech, one should expect the "basic" researchers with no intention to make drugs and no clear sight for drug discovery should be fired. Roche appears to be marking products whether they are discovered internally or in-licensed externally with the aim of growing good investors money; saving patient's lives comes secondary for any capitalistic pharmaceutical company. Genentech is supposed to be a company responsible for investors returns. It is a doing a great job of bringing products and generating revenues; at the same time, like academic institutions, it is wasting a lot of money in basic research that does produce papers in Science and Nature, but better done at academic institutions rather than a money-making machine. One Roche acquires Genentech, one should expect the “basic” researchers with no intention to make drugs and no clear sight for drug discovery should be fired. Roche appears to be marking products whether they are discovered internally or in-licensed externally with the aim of growing good investors money; saving patient’s lives comes secondary for any capitalistic pharmaceutical company.

]]> By: John Wisp http://www.pharmalot.com/2008/08/roche-spins-nj-departure-as-recruiters-eye-genentech/#comment-369800 John Wisp Fri, 22 Aug 2008 09:40:39 +0000 http://www.pharmalot.com/?p=15137#comment-369800 Mr. Silverman, Could you do a side by side comparison of Genentech's and Roche's research track record. Include not only drugs brought to market and revenue generated, but also include publications in major science journals, developed pipelines, and the impact on patients' lives. It should be interesting to see. I look forward to reading your article when you publish. John Mr. Silverman,

Could you do a side by side comparison of Genentech’s and Roche’s research track record. Include not only drugs brought to market and revenue generated, but also include publications in major science journals, developed pipelines, and the impact on patients’ lives. It should be interesting to see. I look forward to reading your article when you publish.

John

]]>